ArticleClinical, cosmetic and investigational dermatology2026
A Reliability Tier Classification System (RTCS) for Marketed Exosome-Based Products to Facilitate Clinical Decision-Making.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Exosomes are nanosized extracellular vesicles involved in intercellular communication. The composition, regulatory status, and scientific support of commercially marketed "exosome-based" products are highly variable, creating challenges for clinicians seeking safe and evidence-informed options in dermatology and aesthetic practice. Objective: The Reliability Tier Classification System (RTCS) was developed to support clinical decision-making. It was designed as a framework-based tool that categorizes exosome-based products and devices intended to enhance exosome release into four reliability tiers. Methods: The RTCS comprises two components: (A) Descriptive Product Classification, and (B) Hierarchical Categorization Algorithm. The first component assesses four domains: (1) regulatory authorization status; (2) origin; (3) manufacturing transparency; and (4) peer-reviewed scientific evidence. The second component assigns four reliability tiers (I-IV). Results: RTCS output standardizes nomenclature for regulatory status (DRUG, MD, COS, NA), origin (AUTO, ALLO, XENO, MIM), and manufacturing reliability (composite transparency score: labeling accuracy, certification disclosure, manufacturing conditions, availability of published clinical evidence, regulatory setbacks, and availability of a detailed exosome production protocol). Conclusion: This clinician-facing tool provides a structured approach to appraising marketed exosome-based products in a rapidly expanding, variably documented marketplace, not yet clinically validated. It is designed to be updateable as regulatory policies and scientific evidence evolve and may serve as a pillar for future implementation and validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.